Fovea Pharmaceuticals

14 articles about Fovea Pharmaceuticals

• 

  European VC Firm Forbion’s Fourth Fund Raises $316 Million

  7/11/2018

  It’s been a big year so far for activity in the U.S. biopharma market—record IPOs and plenty of big acquisitions. But things may be heating up in Europe as well.

• Ariana Pharma Collaborates With Fovea Pharmaceuticals On Phase II Clinical Data Analysis

  2/4/2010

• Sanofi-Aventis (France) to Buy Dyax Corp.'s (JOBS) Drug Development Partner, Fovea Pharmaceuticals

  10/13/2009

• CombinatoRx, Incorporated-Derived Combination Drug Candidate, Prednisporin, Acquired by Sanofi-Aventis K.K. Through Proposed Acquisition of Fovea Pharmaceuticals

  10/5/2009

• Fovea Pharmaceuticals to be Acquired by Sanofi-Aventis (France) for up to $541 Million

  10/1/2009

• Fovea Pharmaceuticals Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis

  5/4/2009

• CombinatoRx, Incorporated Collaborator Fovea Pharmaceuticals Reports Encouraging Clinical Results with CombinatoRx-Derived Combination Drug Candidate

  5/4/2009

• Dyax Corp. (JOBS) and Fovea Pharmaceuticals Sign Development and Commercialization Agreement for DX-88 in Ophthalmic Indications

  2/10/2009

• Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa

  1/7/2008

• Fovea Pharmaceuticals Completes EUR30M Series B Financing

  12/12/2007

• Fovea Pharmaceuticals Enter Into a Research Collaboration in Ophthalmology With Genzyme Corporation

  11/27/2007

• Bernard Davitian, MBA, Appointed EVP & CFO Of Fovea Pharmaceuticals

  10/17/2006

• CombinatoRx, Incorporated And Fovea Pharmaceuticals Enter Into Collaboration To Develop Novel Ophthalmic Therapeutics Built From Synergistic Drug Combinations

  1/31/2006

• Fovea Pharmaceuticals Completes $25 million Series A Financing To Develop New Drugs For Retinal Diseases

  11/7/2005